The New Antidepressants and Antianxieties

(5)
The New Antidepressants and Antianxieties image
ISBN-10:

0452285151

ISBN-13:

9780452285156

Edition: Revised, Updated, Subsequent
Released: Sep 28, 2004
Publisher: Plume
Format: Paperback, 320 pages

Description:

As the number of people suffering from depression rises, so does the number of treatments that flood the market. In this new third edition, Harvard Medical School professor William S. Appleton shares the latest research findings and treatment techniques, along with illuminating case histories, to answer readers’ questions about the new antidepressants and antianxieties. This practical guide includes information on:

The newest antidepressantsLexapro and Cymbalta
Treating anger and irritability, conquering insomnia
A preview of future treatments
How and when to get off the drugs
Side effects such as sexual dysfunction, weight gain, and insomnia

This completely revised and updated edition gives a balanced view of the pros and cons of antidepressants and up-to-the-minute information on all the latest medications and treatments being used to treat depression.

Best prices to buy, sell, or rent ISBN 9780452285156




Related Books

Frequently Asked Questions about The New Antidepressants and Antianxieties

You can buy the The New Antidepressants and Antianxieties book at one of 20+ online bookstores with BookScouter, the website that helps find the best deal across the web. Currently, the best offer comes from and is $ for the .

The price for the book starts from $6.32 on Amazon and is available from 5 sellers at the moment.

If you’re interested in selling back the The New Antidepressants and Antianxieties book, you can always look up BookScouter for the best deal. BookScouter checks 30+ buyback vendors with a single search and gives you actual information on buyback pricing instantly.

As for the The New Antidepressants and Antianxieties book, the best buyback offer comes from and is $ for the book in good condition.

Not enough insights yet.

Not enough insights yet.